Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...
Binhui Biopharmaceutical
Binhui Biopharmaceutical and Topgene Biotechnology Partner for New Drug R&D and AI Platform Development
Wuhan-based Binhui Biopharmaceutical and Hubei Topgene Biotechnology Co., Ltd have announced a strategic partnership to...
Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...